R

oivant, the biotech cephalopod out to weave blockbusters out of pharma’s discard pile, just brought in a superlative amount of money. But for a young firm that has raised both eyebrows and hackles around the industry, the most important detail about its new investment might be the timing.

Roivant, founded and steered by the 32-year-old former hedge fund manager Vivek Ramaswamy, is today $1.1 billion richer thanks to an investor syndicate led by SoftBank, a Japanese telecommunications giant with a $100 billion investment fund.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy